
A Triumph in Diabetes Prevention: Tirzepatide’s Groundbreaking Results in Three-Year Trial
Summary A groundbreaking three-year study reveals that tirzepatide, a dual GIP and GLP-1 receptor agonist, significantly reduces the risk of developing type 2 diabetes by up to 94% in individuals with prediabetes and obesity. Participants […]